Therapeutic Solutions International Announces Positive Preclinical Results Using JadiCells™ in Animal Model of Chronic Obstructive Pulmonary Failure (COPD)

Rhea-AI Summary

Therapeutic Solutions International (OTC Markets: TSOI) announced promising preclinical results using JadiCells™ for treating COPD. In animal studies, JadiCells™ significantly reduced lung damage compared to traditional stem cells and enhanced anti-inflammatory responses. The company is pursuing further exploration of these cells, considering a new IND application. Following successful outcomes in treating COVID-19 patients, TSOI aims to fortify its intellectual property while identifying optimal indications for JadiCells™ development.

Positive

• JadiCells™ demonstrated superior reduction in lung damage compared to other stem cells.
• JadiCells™ showed effective anti-inflammatory properties in the COPD model.
• 100% survival rate in COVID-19 patients under 85 and 91% for those over 85 in previous trials.
• Plans for a new IND application to explore JadiCells™ further.

Negative

• None.

ELK CITY, Idaho, Aug. 23, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced new data and a patent filing covering the use of JadiCells™ and various therapeutic combinations for the treatment of COPD.  The experiments involved administration of JadiCells™ intravenously in animals treated with elastase, a protein that elicits deterioration of the lungs in a manner similar to what occurs in COPD. 

Superior reduction in lung damage was observed in animals receiving JadiCells™ as compared to other clinically used stem cells such as adipose and bone marrow derived mesenchymal stem cells.  In addition, JadiCell™ treated animals possessed significantly decreased expression of the inflammatory proteins toll like receptor 4 and increased expression of the anti-inflammatory protein MerTK.

"The potent anti-inflammatory and regenerative effects of the JadiCells™ have been demonstrated in a variety of in vitro and in vivo settings.  Given the inflammatory nature of COPD, as well as previous studies showing potential of regenerative approaches in this condition^1,2, we examined the potential of these cells to treat an established animal model of COPD," said Dr. James Veltmeyer, Chief Medical Officer of the Company. "Based on the preliminary positive results, as well as what appears to be a unique mechanism of action, we are in the process of continuing our exploration of JadiCells in COPD, which we believe will be the basis for another IND application."

In a double blind, placebo controlled clinical trial, the JadiCell™ was shown to be 100% effective in saving the lives of COVID-19 patients under the age of 85 in a double-blind placebo controlled clinical trial with patients in the ICU on a ventilator. In patients over the age of 85 the survival rate was 91%³.

"From a corporate positioning perspective, we are aiming to concurrently capture as much intellectual property as we can while elucidating in as rapid a manner as possible what indications our JadiCells have the best potential for accelerated development," said Famela Ramos, Vice President of Business Development.

"COPD causes tremendous suffering in patients for which currently there are no curative solutions," stated Timothy Dixon, President and CEO of the Company. "We at Therapeutic Solutions International are committed to cautiously exploring this new potential avenue of research in order to advance science for patients and our shareholders."

About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/ 

1 Therapeutic Solutions International   A placebo-controlled, randomized trial of mesenchymal stem cells in COPD - PubMed (nih.gov)
2 Adipose stem cell treatment in mice attenuates lung and systemic injury induced by cigarette smoking - PubMed (nih.gov)
3 Umbilical cord mesenchymal stem cells for COVID–19 acute respiratory distress syndrome: A double–blind, phase 1/2a, randomized controlled trial - Lanzoni - 2021 - STEM CELLS Translational Medicine - Wiley Online Library

ir@tsoimail.com

View original content:https://www.prnewswire.com/news-releases/therapeutic-solutions-international-announces-positive-preclinical-results-using-jadicells-in-animal-model-of-chronic-obstructive-pulmonary-failure-copd-301360477.html

SOURCE Therapeutic Solutions International

FAQ

What are JadiCells™ and their role in treating COPD?

JadiCells™ are therapeutic cells being investigated for their ability to reduce lung damage and inflammation in COPD.

What were the results of the preclinical trials for JadiCells™?

The trials showed a significant reduction in lung damage and improved inflammatory responses in treated animals compared to other stem cell types.

How did JadiCells™ perform in COVID-19 clinical trials?

JadiCells™ demonstrated a 100% survival rate for COVID-19 patients under 85 and a 91% survival rate for those over 85.

What are the next steps for Therapeutic Solutions International and JadiCells™?

The company plans to pursue a new IND application to explore the therapeutic potential of JadiCells™ for COPD.